0001127602-21-010127.txt : 20210310
0001127602-21-010127.hdr.sgml : 20210310
20210310170850
ACCESSION NUMBER: 0001127602-21-010127
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210303
FILED AS OF DATE: 20210310
DATE AS OF CHANGE: 20210310
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mason Christopher
CENTRAL INDEX KEY: 0001836440
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38537
FILM NUMBER: 21730685
MAIL ADDRESS:
STREET 1: C/O KRYSTAL BIOTECH, INC.
STREET 2: 2100 WHARTON STREET, SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AVROBIO, Inc.
CENTRAL INDEX KEY: 0001681087
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 810710585
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BLDG. 300, SUITE 201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 7819626030
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BLDG. 300, SUITE 201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AvroBio, Inc.
DATE OF NAME CHANGE: 20160729
3
1
form3.xml
PRIMARY DOCUMENT
X0206
3
2021-03-03
0
0001681087
AVROBIO, Inc.
AVRO
0001836440
Mason Christopher
C/O AVROBIO, INC.
ONE KENDALL SQUARE, BLDG. 300, SUITE 201
CAMBRIDGE
MA
02139
1
Chief Scientific Officer
Common Stock
284365
D
Stock Option (Right to Buy)
.41
2026-04-12
Common Stock
70587
D
Stock Option (Right to Buy)
1.20
2026-10-24
Common Stock
27658
D
Stock Option (Right to Buy)
.91
2027-06-12
Common Stock
21708
D
Stock Option (Right to Buy)
5.00
2028-03-15
Common Stock
29633
D
Stock Option (Right to Buy)
16.98
2029-02-24
Common Stock
50000
D
Stock Option (Right to Buy)
21.44
2030-03-03
Common Stock
76000
D
Stock Option (Right to Buy)
16.02
2031-02-03
Common Stock
125000
D
25% of the shares vested on July 1, 2017, and the remaining 75% vested in equal quarterly installments thereafter over a three-year period.
25% of the shares vested on October 25, 2017, and the remaining 75% vested in equal quarterly installments thereafter over a three-year period.
25% of the shares vested on June 13, 2018, and the remaining 75% vest in equal quarterly installments thereafter over a three-year period.
25% of the shares vested on March 16, 2019, and the remaining 75% vest in equal quarterly installments thereafter over a three-year period.
25% of the shares vested on February 25, 2020, and the remaining 75% vest in equal quarterly installments thereafter over a three-year period.
25% of the shares vested on February 3, 2021, and the remaining 75% vest in equal quarterly installments thereafter over a three-year period.
25% of the shares shall vest on February 4, 2022, and the remaining 75% shall vest in equal quarterly installments thereafter over a three-year period.
Exhibit 24 - Power of Attorney
/s/ Christopher Gerry, Attorney in Fact for Christopher Mason
2021-03-10
EX-24
2
doc1.txt
POWER OF ATTORNEY (PUBLIC): POWER OF ATTORNEY
LIMITED POWER OF ATTORNEY
The undersigned hereby constitutes and appoints each of Steven Avruch,
Christopher Gerry, Marcia Gookin, Arthur R. McGivern, and James Xu,
signing singly, and with full power of substitution, as the undersigned's
true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's
capacity as officer and/or director of AVROBIO, Inc. (the "Company"), from
time to time the following U.S. Securities and Exchange Commission ("SEC")
forms: (i) Form ID, including any attached documents (such as Update
Passphrase Authentication), to effect the assignment of codes to the
undersigned to be used in the transmission of information to the SEC
using the EDGAR System; (ii) Form 3, Initial Statement of Beneficial
Ownership of Securities, including any attached documents; (iii)
Form 4, Statement of Changes in Beneficial Ownership of Securities,
including any attached documents; (iv) Form 5, Annual Statement of
Beneficial Ownership of Securities in accordance with Section 16(a)
of the Securities Exchange Act of 1934, as amended, and the rules
thereunder, including any attached documents; (v) Schedules 13D and
13G and (vi) amendments of each thereof, in accordance with the Securities
Exchange Act of 1934, as amended, and the rules thereunder, including any
attached documents;
(2) do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Form 3, 4
or 5, Schedules 13D and 13G or any amendment(s) thereto, and timely file such
form(s) with the SEC and any securities exchange, national association or
similar authority; and
(3) take any other action of any type whatsoever in connection with
the foregoing which, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of
the undersigned pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve
in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact, acting
singly, full power and authority to do and perform any and every act and
thing whatsoever requisite, necessary or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all intents and
purposes as the undersigned might or could do if personally present, with
full power of substitution or revocation, hereby ratifying and confirming
all that such attorney-in-fact, or such attorney-in-fact's substitute or
substitutes, shall lawfully do or cause to be done by virtue of this power
of attorney and the rights and powers herein granted. The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such
capacity at the request of the undersigned, are not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as
amended. The undersigned hereby agrees to indemnify the attorneys-in- fact
and the Company from and against any demand, damage, loss, cost or expense
arising from any false or misleading information provided by the undersigned
to the attorneys-in-fact.
This Power of Attorney shall remain in full force and effect until
the undersigned is no longer required to file such forms with respect to the
undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact. This Power of Attorney
supersedes any prior power of attorney in connection with the undersigned's
capacity as an officer and/or director of the Company. This Power of
Attorney shall expire as to any individual attorney-in-fact if such
attorney-in-fact ceases to be an executive officer of, or legal
counsel to, the Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of March 4, 2021.
_/s/ Christopher Mason _____
Name: Christopher Mason